Succinic acid
Succinic acid
110-15-6
disodium succinate
Phthalocyanine pigment
Compound dyes
Compound green
Composite blue
(2-heteroarylamino) succinic acid(cas:110-15-6) derivatives
Release time:2016/8/3 17:23:57

The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by the formula (1) wherein R1: an aromatic hydrocarbon ring group or an aromatic heterocyclic group; R2: a hydrogen atom, an alkyl group, or a heterocycloalkyl group; R3: a hydrogen atom or an alkyl group; A: a hydrogen atom or a hydroxy group; L: —NHCO— or —OCH2—; and X: a nitrogen atom or ═CH—.

SUMMARY OF INVENTION
Technical Problem of the Invention

The inventors of the present invention conducted studies for the purpose of providing novel low molecular weight compounds that have a superior EPO production-enhancing activity and that are useful for the treatment of diseases caused by decreased EPO, and for the purpose of providing a medicament containing such compounds.


Means for Solution to the Problem

In order to solve the aforementioned problems, the inventors of the present invention found that novel compounds having a (2-heteroarylamino)succinic acid structure have a superior EPO production-enhancing activity and that they are effective for treating diseases caused by decreased EPO, thereby leading to completion of the present invention.


According to the present invention, novel (2-heteroarylamino)succinic acid(cas:110-15-6) compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof (hereinafter collectively referred to as compounds of the present invention), are provided.


Industrial Applicability
The compounds of the present invention or pharmacologically acceptable salts thereof have a superior EPO production-enhancing activity, and are useful for diseases caused by decreased EPO or the like. Specifically, the compounds of the present invention or pharmacologically acceptable salts thereof are useful as medicaments for the prophylaxis and/or treatment of anemia, preferably nephrogenic anemia, anemia of prematurity, anemia incidental to chronic diseases, anemia incidental to cancer chemotherapy, cancerous anemia, inflammation-associated anemia, or anemia incidental to congestive heart failure, more preferably anemia incidental to chronic kidney disease, and can also be used as medicaments for the prophylaxis and/or treatment of ischemic cerebrovascular disease or the like.

Return >> 
Home | About Us | Products | Honors | Facility | Order | Contact | News | 中文版
Copyright(C)2013, Anhui Sunsing Chemicals Co.,Ltd. All Rights Reserved.Supported by Lookchem Copyright Notice